Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

MENLO PARK, Calif., March 07, 2017 -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it has closed its previously announced public offering of 5,750,000 shares of its common stock, including 750,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock, at a price to the public of $33.70 per share.  All of the shares were sold by Dermira. The aggregate gross proceeds to Dermira from the offering, before deducting the underwriting discounts and commissions and offering expenses, were approximately $193.8 million.

Leerink Partners LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC acted as joint book-running managers for the offering. Needham & Company, LLC acted as co-manager.

The public offering was made pursuant to a shelf registration statement on Form S-3 that was filed by Dermira with the Securities and Exchange Commission (“SEC”) and became automatically effective on February 28, 2017. This offering was made solely by means of a prospectus supplement and accompanying prospectus relating to and describing the terms of the offering, copies of which may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at [email protected], or by telephone at 800-808-7525, ext. 6142; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, or by email at [email protected]; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, or by email at [email protected], or by telephone at 212-518-9658.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy Dermira’s common stock, nor shall there be any sale of Dermira’s common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contacts:

Media:  
Erica Jefferson
Senior Director, Head of Corporate Communications
650-421-7216
[email protected]

Investors:
Andrew Guggenhime
Chief Operating Officer and Chief Financial Officer 
650-421-7200
[email protected]

Robert H. Uhl
Westwicke Partners
Managing Director
858-356-5932
[email protected]